Bispecific Nanobody Broadly Neutralizes and Cross-Protects against Three Highly Pathogenic Human Coronaviruses
Abstract SARS-CoV, SARS-CoV-2, and MERS-CoV continue to infect humans or pose a threat of future outbreaks, highlighting the ongoing need for effective, broad-spectrum therapeutics that target these highly pathogenic coronaviruses. As single-domain antibodies, nanobodies have a small size, high target-binding affinity, exceptional stability, low production costs, and the ability to access otherwise hidden or cryptic epitopes. Here, we identified nanobodies targeting SARS-CoV, SARS-CoV-2, and MERS-CoV receptor-binding domains (RBDs) using phage display libraries derived from immunized nanomice and generated a bispecific nanobody to evaluate its broadly neutralizing activity and cross-protective efficacy. Nanobodies 2F11 and 4D6 targeted SARS-CoV RBD, potently neutralizing the SARS-CoV original (Tor2) strain, whereas nanobody 3B11 targeted both SARS-CoV and SARS-CoV-2 RBDs, broadly neutralizing all three SARS-CoV strains (Tor2, GD03, and SZ3) and divergent SARS-CoV-2 variants. Among MERS-CoV RBD-targeting nanobodies, 1C11 demonstrated broadly neutralizing activity against multiple MERS-CoV strains, while its Fc-fused version substantially enhanced the neutralizing potency. These nanobodies exerted neutralizing effects by blocking the interaction between the RBDs and their respective receptors. Cryo-EM structures, computational modeling, and epitope-mapping analyses revealed unique epitopes of 2F11, 3B11, and 1C11 on the SARS-CoV, SARS-CoV-2, or MERS-CoV RBD, underlying their antiviral potency. Finally, a bispecific nanobody 3B11–1C11-Fc that binds to the SARS-CoV, SARS-CoV-2, and MERS-CoV RBDs exhibited high stability and robust cross-neutralizing activity against all tested SARS-CoV, SARS-CoV-2, and MERS-CoV strains, protecting mice from infection with these three coronaviruses. Overall, the identified nanobodies, particularly the bispecific nanobody, exhibit strong neutralizing potency and protective efficacy against SARS-CoV, SARS-CoV-2, and MERS-CoV, showing the potential for further therapeutic development.
Authors
- Lanying Du (ORCID: https://orcid.org/0000-0001-5955-1294)
- Parisa Darvishi
- Li Yu (ORCID: https://orcid.org/0000-0002-3757-0758)
- Fang Li (ORCID: https://orcid.org/0000-0002-9152-1850)
- Shengnan Qian
- Xiaoqing Guan (ORCID: https://orcid.org/0000-0002-5513-4968)
- Wandi Zhu (ORCID: https://orcid.org/0000-0002-8395-5392)
- Abhijeet Roy
- Rhea Guo (ORCID: https://orcid.org/0009-0001-4836-5602)
- Stanley Perlman
- Jianliang Xu
- Chang Liu
- Abhishek K. Verma
- Qian Liu
- Hansam Cho
- Yang Yang
Institutions
- The Wistar Institute (US)
- University of Iowa (US)
- University of Minnesota (US)
- Johns Hopkins University (US)
- Iowa State University (US)
- Georgia State University (US)
Publication Details
- Journal
- ACS Nano
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1021/acsnano.6c10948
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of General Medical Sciences
- National Institute of Allergy and Infectious Diseases